Indications

• Chronic Obstructive Pulmonary Disease (COPD) (see Chronic Obstructive Pulmonary Disease, [[Chronic Obstructive Pulmonary Disease]])
  • Indacaterol is not indicated for asthma

---

Pharmacology

• Ultra Long-Acting β2-Adrenergic Receptor Agonist (see β2-Adrenergic Receptor Agonists, [[β2-Adrenergic Receptor Agonists]]): 24 hr sustained bronchodilation
  • Improved FEV1: fast onset of action (FEV1 improvement is seen as early as 5 min after dose)
  • Decreased rescue medication use
  • Improved health-related quality of life (by St. George’s respiratory questionnaire)

---

Administration

• INH: 75 ug qday (dry powder capsule, used in neohaler device)

---

Adverse Effects

Pulmonary Adverse Effects

• Cough (see Cough, [[Cough]])
• Nasopharyngitis (see Pharyngitis, [[Pharyngitis]])
• LABA FDA Black-Box Warning in Asthma: all LABA’s carry this warning, although indacaterol is not indicated for asthma

Gastrointestinal Adverse Effects

• Nausea (see Nausea and Vomiting, [[Nausea and Vomiting]])

Neurological Adverse Effects

• Headache (see Headache, [[Headache]])

Other Adverse Effects

• xxx

---

References

• xxx